Member Info for solstace

https://twitter.com/Soulbythewater/status/1471139999039078412?t=ItjwQo42gff-ycfkosL1oQ&s=19

In favour of mandatory face coverings!

Is really getting stuck in!! Lots being addressed and put in place for the 1st of January........................

Is excellent, new marketing manager hired, global production and distribution partners being lined up!!!!! Get in Mark!!!!

https://*************************/status/1471020539661537280?t=EjWiQeAdEoN45DPigM5pSw&s=19

https://www.westmeathindependent.ie/2021/12/13/grants-of-e62m-announced-for-air-filters-and-ventilation-works-in-schools/

Gearing up ready for something........

Lol phat fingers Volz UK

In October Investing in bigger, better, faster production machinery!

https://www.etmm-online.com/edm-installation-ensures-productivity-gains-for-british-subcontractor-a-1082348/

https://twitter.com/Ai_Diagnostics/status/1469719563608723458?t=xLAaE-pISr6-T-k-LVbcHg&s=19

https://twitter.com/Soulbythewater/status/1469207223977095168?s=20

https://www.bbc.co.uk/news/health-59580290

T-cells are another part of your body's defences and they learn to recognise when cells in your body have been infected with coronavirus and promptly destroy them.
T-cells are much better at dealing with new variants. Early analysis suggests 80% of the parts of the virus that vaccines have trained T-cells to attack are unchanged in Omicron.

Mystery et Al Obviously have issues! Best just to ignore them!

Sounds to me like some big news is incoming in a week or two, NDA's with Pharma's are common place hence no leaks so far!

Looks a good solid investment! Sustained growth!

News on AZD1656 in 2-4weeks will be what hopefully fires us into orbit! GLA

https://scitechdaily.com/new-covid-19-treatment-for-people-with-diabetes-shows-early-promise/

The trial reduced the number of deaths in patients receiving AZD1656, a promising finding which will need to be analyzed further by the researchers, when cellular immunology results become available, before the study results undergo peer review. The reduced mortality for patients on AZD1656 was observed on top of benefits from other medications, such as dexamethasone, as part of standard of care. AZD1656 was shown to be well-tolerated with no serious adverse reactions occurring.

On Thursday this week, the team’s work was recognized at a reception at 10 Downing Street attended by Professor Martin. The reception was held to celebrate the UK-United Arab Emirates prosperity and innovation partnership, as the UAE’s sovereign wealth fund contributed to the trial’s funding.

Professor Martin, Chairman of SGSC and Principal Investigator on the UKRI grant said: “We have demonstrated our ability to rapidly deliver a clinical trial in 16 months from conception to completion. The promising results from this trial indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for Covid-19. It is beneficial regardless of viral mutations. It is the first specific treatment for Covid disease (as opposed to antivirals or vaccines) and may herald a new field of drugs activating cells in the body which become themselves the therapeutic agent.”

Yawn

AZD1656 Activates your bodies own defences, namely T-cells!

The Omicron variant has a large number of mutations compared with previous variants, more than 30 of which are in the spike protein – the key used by the virus to enter our body’s cells. Such a dramatic change has raised concerns that the antibodies from previous infections or vaccination may no longer be well matched, although it’s likely that some residual immunity, for example from T-cells, will remain.